Novartis announces new data on phase III clinical study of anti-inflammatory drug Cosentyx (good) treatment nr-axSpA
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, SwissPharmaceutical
s (http://giant Novartis has released new data on the treatment of the anti-inflammatory drug Cosentyx (co-cuminumab, scucciuumab, scochiu) for the efficacy and safety of phase III clinical studies of patients with radiology-negative axial spinal arthritis (nr-axSpA)The data showed a significant and clinical lyno reduction in disease activity in the Cosentyx treatment group compared to the placebo groupThe study also reached all secondary endpointsIn the study, Cosentyx had good safety and was consistent with previous clinical studiesAbout Cosentyx
Cosentyx is the first and only specific target inhibition of leukin-17A (IL-17A) of all-human monoclonal antibodies
drug(http://that selectively targets the ability to block the activity of circulating IL-17A, reduce immune system activity and improve disease symptomsThe study revealed that IL-17A plays an important role in driving inflammation and development of a variety of autoimmune diseases in the body, including psoriasis arthritis (PsA), psoriasis (PsO), and strong scoliosis (AS)Cosentyx was approved for the market in January 2015 and has now been approved for three indications (PsO, PsA, AS)In China, Cosentyx was approved by the NationalMedicines (http:// Supervision Authority (NMPA) at the end of March this year to treat adult patients with moderate to severe plaque psoriasis that meets the signs of systemic therapy or phototherapy
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
